This article has been peer reviewed and accepted for publication. It is in production and has not been edited, so may differ from the final published form.
Medicare needs to consider banning harmful knee OA treatments, not effective ones
We would like to engage further correspondence on the paper of Mundy, which has recently moved from online to in print, regarding Medicare ‘divestment’ of PRP (platelet rich plasma) for knee OA (osteoarthritis), in light of new published evidence.
AH17131 Accepted 06 June 2017
© CSIRO 2017